|
ZA201600076B
|
|
Compositions and methods for modulating hbv and ttr expression
|
|
US2016017324A1
|
|
Chimeric oligomeric compounds and their use in gene modulation
|
|
WO2015188194A1
|
|
Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
|
|
WO2015187989A1
|
|
Antisense compounds targeting apolipoprotein e receptor 2
|
|
WO2015179693A1
|
|
Conjugated antisense compounds and their use
|
|
CN106232125A
|
|
For regulating compositions and the method that PKK expresses
|
|
WO2015168172A1
|
|
Linkage modified oligomeric compounds
|
|
WO2015153800A2
|
|
Compositions for modulating sod-1 expression
|
|
WO2015143245A1
|
|
Methods for modulating ataxin 2 expression
|
|
WO2015142910A1
|
|
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
|
AU2015201226A1
|
|
Modulation of hepatitis b virus (hbv) expression
|
|
US2015184157A1
|
|
Modulation of transthyretin expression
|
|
WO2015070173A1
|
|
Compounds and methods for detecting oligonucleotides
|
|
WO2015061246A1
|
|
Method for solution phase detritylation of oligomeric compounds
|
|
WO2015054579A1
|
|
Treatment of acute kidney injury with phd1 modulators
|
|
TW201536329A
|
|
Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
|
|
WO2014201413A1
|
|
Compounds and methods for modulating non-coding rna
|
|
MA46019A1
|
|
Compositions and methods for modulating the expression of hbv and ttr
|
|
WO2014172698A1
|
|
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
|
WO2014160211A1
|
|
Modulation of inflammatory responses by c-reactive protein
|
